Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 238

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia

Open access
Quintás-Cardama, Alfonso, Kantarjian, Hagop M., Cortes, Jorge E.·2009·Cancer Control
DOI 10.1177/107327480901600204
Open this paper in CoChat — free account

Abstract

BACKGROUND: Although the vast majority of patients with chronic myeloid leukemia (CML) respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de novo or during treatment. METHODS: The authors reviewed the known mechanisms of primary and secondary resistance to imatinib and other TKIs used in the management of CML. RESULTS: Mutations within the kinase domain of BCR-ABLI account for 30% to 40% of cases of imatinib resistance. Other mechanisms include BCR-ABLI amplification, overexpression of the SRC family of kinases, and pharmacokinetic and pharmacodynamic factors. CONCLUSIONS: Although not all resistance mechanisms have been identified and understood, several agents based on the known mechanisms have already been designed and developed and are beginning clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/107327480901600204

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 97

  1. Nowell P.C., 1960, Science., 132, 1497
  2. Bartram C.R., 1983, Nature., 306, 277, 10.1038/306277a0 · DOI · Paper page
  3. Groffen J., 1984, Cell., 36, 93, 10.1016/0092-8674(84)90077-1 · DOI · Paper page
  4. Ramaraj P., 2004, Cancer Res., 64, 5322, 10.1158/0008-5472.CAN-03-3656 · DOI · Paper page
  5. Zhao R.C., 2001, Blood., 97, 2406, 10.1182/blood.V97.8.2406 · DOI · Paper page
  6. Daley G.Q., 1990, Science., 247, 824, 10.1126/science.2406902 · DOI · Paper page
  7. Kelliher M.A., 1990, Proc Natl Acad Sci U S A., 87, 6649, 10.1073/pnas.87.17.6649 · DOI · Paper page
  8. Zhang X., 1998, Blood., 92, 3829, 10.1182/blood.V92.10.3829 · DOI · Paper page
  9. Hochhaus A., 2007, Blood (ASH Annual Meeting Abstracts)., 110
  10. Druker B.J., 2006, N Engl J Med., 355, 2408, 10.1056/NEJMoa062867 · DOI · Paper page
  11. Druker B.J., 2001, N Engl J Med., 344, 1038, 10.1056/NEJM200104053441402 · DOI · Paper page
  12. Ren R., 2005, Nat Rev Cancer., 5, 172, 10.1038/nrc1567 · DOI · Paper page
  13. Druker B.J., 1996, Nat Med., 2, 561, 10.1038/nm0596-561 · DOI · Paper page
  14. Beran M., 1998, Clin Cancer Res., 4, 1661
  15. Gambacorti-Passerini C., 1997, Blood Cells Mol Dis., 23, 380, 10.1006/bcmd.1997.0155 · DOI · Paper page
  16. O'Brien S.G., 2003, N Engl J Med., 348, 994, 10.1056/NEJMoa022457 · DOI · Paper page
  17. Saldanha J., 2007, Leukemia., 21, 1481, 10.1038/sj.leu.2404716 · DOI
  18. Branford S., 2006, Leukemia., 20, 1925, 10.1038/sj.leu.2404388 · DOI · Paper page
  19. Morley A., 2007, Blood (ASH Annual Meeting Abstracts)., 110
  20. Baccarani M., 2006, Blood., 108, 1809, 10.1182/blood-2006-02-005686 · DOI · Paper page
  21. le Coutre P., 2004, Cancer Chemother Pharmacol., 53, 313, 10.1007/s00280-003-0741-6 · DOI · Paper page
  22. Peng B., 2004, J Clin Oncol., 22, 935, 10.1200/JCO.2004.03.050 · DOI · Paper page
  23. Picard S., 2007, Blood., 109, 3496, 10.1182/blood-2006-07-036012 · DOI · Paper page
  24. Gambacorti-Passerini C., 2000, J Natl Cancer Inst., 92, 1641, 10.1093/jnci/92.20.1641 · DOI · Paper page
  25. Jørgensen H.G., 2002, Blood., 99, 713, 10.1182/blood.V99.2.713 · DOI
  26. Mahon F.X., 2000, Blood., 96, 1070, 10.1182/blood.V96.3.1070 · DOI · Paper page
  27. Dai H., 2003, J Pharmacol Exp Ther., 304, 1085, 10.1124/jpet.102.045260 · DOI · Paper page
  28. Mahon F.X., 2003, Blood., 101, 2368, 10.1182/blood.V101.6.2368 · DOI · Paper page
  29. Thomas J., 2004, Blood., 104, 3739, 10.1182/blood-2003-12-4276 · DOI · Paper page
  30. Ferrao P.T., 2003, Blood., 102, 4499, 10.1182/blood-2003-01-0083 · DOI
  31. Galimberti S., 2005, Cancer Genet Cytogenet., 162, 57, 10.1016/j.cancergencyto.2005.01.015 · DOI
  32. Jordanides N.E., 2006, Blood., 108, 1370, 10.1182/blood-2006-02-003145 · DOI · Paper page
  33. Crossman L.C., 2005, Blood., 106, 1133, 10.1182/blood-2005-02-0694 · DOI · Paper page
  34. Kim D.H., 2007, Blood (ASH Annual Meeting Abstracts)., 110
  35. Komarova N.L., 2007, PLoS ONE., 2, e990, 10.1371/journal.pone.0000990 · DOI
  36. Michor F., 2005, Nature., 435, 1267, 10.1038/nature03669 · DOI · Paper page
  37. Roeder I., 2006, Nat Med., 12, 1181, 10.1038/nm1487 · DOI · Paper page
  38. Holtz M.S., 2005, Leukemia., 19, 1034, 10.1038/sj.leu.2403724 · DOI
  39. Holtz M.S., 2002, Blood., 99, 3792, 10.1182/blood.V99.10.3792 · DOI · Paper page
  40. Graham S.M., 2002, Blood., 99, 319, 10.1182/blood.V99.1.319 · DOI · Paper page
  41. Konig H., 2008, Blood., 111, 2329, 10.1182/blood-2007-05-092056 · DOI
  42. Lahaye T., 2005, Cancer., 103, 1659, 10.1002/cncr.20922 · DOI · Paper page
  43. Jabbour E., 2006, Leukemia., 20, 1767, 10.1038/sj.leu.2404318 · DOI · Paper page
  44. Johansson B., 2002, Acta Haematol., 107, 76, 10.1159/000046636 · DOI · Paper page
  45. Jennings B.A., 1998, Leuk Res., 22, 899, 10.1016/S0145-2126(98)00097-6 · DOI
  46. Calabretta B., 2004, Blood., 103, 4010, 10.1182/blood-2003-12-4111 · DOI · Paper page
  47. Gaiger A., 1995, Blood., 86, 2371, 10.1182/blood.V86.6.2371.bloodjournal8662371 · DOI · Paper page
  48. Wendel H.G., 2006, Proc Natl Acad Sci U S A., 103, 7444, 10.1073/pnas.0602402103 · DOI
  49. Quintás-Cardama A., 2006, Mayo Clin Proc., 81, 973, 10.4065/81.7.973 · DOI · Paper page
  50. Huntly B.J., 2003, Blood., 102, 1160, 10.1182/blood-2003-01-0123 · DOI
  51. Abram C.L., 2000, Exp Cell Res., 254, 1, 10.1006/excr.1999.4732 · DOI · Paper page
  52. Stanglmaier M., 2003, Leukemia., 17, 283, 10.1038/sj.leu.2402778 · doi:10.1038/sj.leu.2402778
  53. Danhauser-Riedl S., 1996, Cancer Res., 56, 3589
  54. Hu Y., 2004, Nat Genet., 36, 453, 10.1038/ng1343 · DOI · Paper page
  55. Bhatia R., 2003, Blood., 101, 4701, 10.1182/blood-2002-09-2780 · DOI · Paper page
  56. Kerkhoff E., 1998, Oncogene., 17, 1457, 10.1038/sj.onc.1202185 · DOI · Paper page
  57. Nosaka T., 1999, EMBO J., 18, 4754, 10.1093/emboj/18.17.4754 · DOI · Paper page
  58. Dai Y., 2004, J Biol Chem., 279, 34227, 10.1074/jbc.M402290200 · DOI · Paper page
  59. Donato N.J., 2003, Blood., 101, 690, 10.1182/blood.V101.2.690 · DOI · Paper page
  60. Donato N.J., 2004, Cancer Res., 64, 672, 10.1158/0008-5472.CAN-03-1484 · DOI · Paper page
  61. Hofmann W.K., 2002, Lancet., 359, 481, 10.1016/S0140-6736(02)07678-X · DOI · Paper page
  62. Wu J., 2008, Blood., 111, 3821, 10.1182/blood-2007-08-109330 · DOI
  63. Hochhaus A., 2002, Leukemia., 16, 2190, 10.1038/sj.leu.2402741 · DOI · Paper page
  64. Barnes D.J., 2005, Cancer Res., 65, 8912, 10.1158/0008-5472.CAN-05-0076 · DOI · Paper page
  65. Hochhaus A., 2004, Leukemia., 18, 1321, 10.1038/sj.leu.2403426 · DOI · Paper page
  66. Shah N.P., 2002, Cancer Cell., 2, 117, 10.1016/S1535-6108(02)00096-X · DOI · Paper page
  67. Löwenberg B., 2003, N Engl J Med., 349, 1399, 10.1056/NEJMp038130 · DOI · Paper page
  68. Corbin A.S., 2003, Blood., 101, 4611, 10.1182/blood-2002-12-3659 · DOI · Paper page
  69. Gambacorti-Passerini C.B., 2003, Lancet Oncol., 4, 75, 10.1016/S1470-2045(03)00979-3 · DOI · Paper page
  70. Hughes T., 2006, Blood Rev., 20, 29, 10.1016/j.blre.2005.01.008 · DOI · Paper page
  71. Cortes J., 2007, Blood., 110, 4005, 10.1182/blood-2007-03-080838 · DOI · Paper page
  72. Schindler T., 2000, Science., 289, 1938, 10.1126/science.289.5486.1938 · DOI · Paper page
  73. Nagar B., 2002, Cancer Res., 62, 4236
  74. Weisberg E., 2005, Cancer Cell., 7, 129, 10.1016/j.ccr.2005.01.007 · DOI · Paper page
  75. Kantarjian H., 2006, N Engl J Med., 354, 2542, 10.1056/NEJMoa055104 · DOI · Paper page
  76. Lombardo L.J., 2004, J Med Chem., 47, 6658, 10.1021/jm049486a · DOI · Paper page
  77. Shah N.P., 2004, Science., 305, 399, 10.1126/science.1099480 · DOI · Paper page
  78. Weisberg E., 2006, Br J Cancer., 94, 1765, 10.1038/sj.bjc.6603170 · DOI · Paper page
  79. Hantschel O., 2003, Cell., 112, 845, 10.1016/S0092-8674(03)00191-0 · DOI · Paper page
  80. Azam M., 2003, Cell., 112, 831, 10.1016/S0092-8674(03)00190-9 · DOI · Paper page
  81. Quintás-Cardama A., 2007, Blood (ASH Annual Meeting Abstracts)., 110
  82. Hughes T., 2006, Blood., 108, 28, 10.1182/blood-2006-01-0092 · DOI · Paper page
  83. Deininger M., 2005, Blood., 105, 2640, 10.1182/blood-2004-08-3097 · DOI · Paper page
  84. Carter T.A., 2005, Proc Natl Acad Sci U S A., 102, 11011, 10.1073/pnas.0504952102 · DOI · Paper page
  85. Branford S., 2003, Blood., 102, 276, 10.1182/blood-2002-09-2896 · DOI · Paper page
  86. Soverini S., 2005, J Clin Oncol., 23, 4100, 10.1200/JCO.2005.05.531 · DOI · Paper page
  87. Apperley J.F., 2007, Lancet Oncol., 8, 1018, 10.1016/S1470-2045(07)70342-X · DOI · Paper page
  88. Weisberg E., 2007, Nat Rev Cancer., 7, 345, 10.1038/nrc2126 · DOI · Paper page
  89. Khorashad J.S., 2006, Leukemia., 20, 658, 10.1038/sj.leu.2404137 · DOI
  90. Skaggs B.J., 2006, Proc Natl Acad Sci U S A., 103, 19466, 10.1073/pnas.0609239103 · DOI
  91. Griswold I.J., 2006, Mol Cell Biol., 26, 6082, 10.1128/MCB.02202-05 · DOI · Paper page
  92. Shah N.P., 2007, J Clin Invest., 117, 2562, 10.1172/JCI30890 · DOI · Paper page
  93. Deininger M.W., 2004, Leukemia., 18, 864, 10.1038/sj.leu.2403307 · DOI
  94. Soverini S., 2004, Clin Chem., 50, 1205, 10.1373/clinchem.2004.031112 · DOI
  95. Ernst T., 2008, Haematologica., 93, 186, 10.3324/haematol.11993 · DOI
  96. Willis S.G., 2005, Blood., 106, 2128, 10.1182/blood-2005-03-1036 · DOI · Paper page
  97. Nardi V., 2008, Oncogene., 27, 775, 10.1038/sj.onc.1210698 · DOI

Cited by

See all 238

Metadata

Authors
Quintás-Cardama, A., Kantarjian, H. M., & Cortes, J. E.
Venue
Cancer Control
Publisher
SAGE Publications
Published
2009-04
Volume
16
Issue
2
Pages
122-131
ISSN
1073-2748 (ISSN-L)
DOI
10.1177/107327480901600204
OpenAlex
W2152648806
Cited by
238
References
7
FWCI
16.24
Type
journal article
Language
en
Open access
bronze
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia. https://app.cochat.ai/papers/10.1177/107327480901600204
The paper
Quintás-Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009). Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia. Cancer Control. https://doi.org/10.1177/107327480901600204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.